Company intelligence / Profile preview

TYRX, Inc.

Monmouth Junction, New Jersey, United Statesbiospace.com ↗

Ownership: Private
Development stage: Commercial

Overview

TYRX developed and commercialized the AIGISRx line of antibacterial envelopes and flat sheets for use with implantable cardiac electronic devices to reduce the risk of post-surgical infections. The products contain rifampin and minocycline embedded in a bioabsorbable polymer matrix, providing localized antibiotic delivery at the implantation site[2][4][5]. Clinical adoption included over 13,000 patients by 2010[5].

Therapeutic areas: Infectious Diseases
Modalities: DevicePolymer-drug conjugate therapySmall molecule (antibiotics)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

PIVIT CRM

NDA

Indications: Surgical site infections

Partnerships

Rutgers University (technology licensing)Baylor College of Medicine & MD Anderson Cancer Center (technology licensing)

Beyond the preview

Go deeper on TYRX, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TYRX, Inc..

Explore the full profile